First Header Logo Second Header Logo

Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.

Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz HJ. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. J Clin Oncol. 2008 May 10; 26(14):2320-6.

View in: PubMed